Table 1 Demographic and clinical characteristics of study sample
| Â | n | %(n) or M(SD) |
|---|---|---|
Sex, % Female | 109 | 55.04% (60) |
Race | 109 | Â |
 White |  | 79.82% (87) |
 Black |  | < 1% (1) |
 Asian |  | 15.60% (17) |
 Other |  | 4.59% (5) |
Age (years) | 109 | 73.2(8.1) |
Education (years) | 109 | 17.5(1.9) |
Body mass index (BMI) | 109 | 25.4(4.9) |
APOE Status | 96 | Â |
 E2/E3 |  | 10.42% (10) |
 E2/E4 |  | 1% (1) |
 E3/E3 |  | 65.6% (63) |
 E3/E4 |  | 21.9% (21) |
 E4/E4 |  | 1% (1) |
Hypertension, % recent/active history | 101 | 31.68% (32) |
Anti-hypertensive medication, % current use | 108 | 34.26% (37) |
Cardiovascular indicators | Â | Â |
 Systolic blood pressure (BP, mmHg) | 109 | 132.7(16.4) |
 Diastolic BP (mmHg) | 109 | 74.0(9.6) |
 Pulse pressure (systolic BP-diastolic BP, mmHg) | 109 | 58.7(14.1) |
Plasma biomarkers (pg/mL) | Â | Â |
 Amyloid beta 42/40 ratio (Aβ42/40) | 107 | 0.6(0.01) |
 Glial fibrillary acidic protein (GFAP) | 109 | 167.9(87.5) |
 Neurofilament light chain (NfL) | 109 | 29.6(14.6) |
 Tau phosphorylated at threonine-181 (pTau181) | 98 | 3.8(2.1) |